Targeting heparan sulfate proteoglycans in breast cancer treatment.

Article Details

Citation

Copy to clipboard

Koo CY, Sen YP, Bay BH, Yip GW

Targeting heparan sulfate proteoglycans in breast cancer treatment.

Recent Pat Anticancer Drug Discov. 2008 Nov;3(3):151-8.

PubMed ID

18991783 [ View in PubMed

]

Abstract

Breast carcinoma is one of the leading causes of mortality among female cancers globally. Heparan sulfate proteoglycans, found predominantly on cell surfaces and in the extracellular matrix, are known to regulate breast cancer cellular behavior. Many studies have shown that these molecules serve as potential biomarkers for breast cancer. In addition, they have aberrant expression patterns and participate in various molecular signaling pathways in tumor progression. There is substantial interest in targeting heparan sulfate proteoglycans for cancer treatment, which needs to be tailored according to the roles that each proteoglycan plays in cancer biology. Current clinical trials using phosphomannopentaose sulfate, a heparan sulfate mimic, and various forms of heparin have produced promising results in breast cancer patients. Besides heparan sulfate chains, novel therapeutic agents could potentially be developed to regulate the proteoglycan core proteins as well as enzymes that modify heparan sulfation patterns. This review discusses the current use and future prospective applications of heparan sulfate proteoglycans, which have been recently patented, as therapeutic targets in breast cancer treatment.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Tinzaparin	Stromal cell-derived factor 1	Protein	Humans	Unknown	Binder	Details